Protein Kinase C (PKC) Inhibitors:阻害薬のグローバル市場2014(薬開発、治験動向)

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DIMR2014588)
◆英語タイトル:Protein Kinase C (PKC) Inhibitors -Pipeline Insights, 2014
◆発行会社/調査会社:DelveInsight
◆商品コード:DIMR2014588
◆発行日:2014年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥136,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Protein Kinase C (PKC) Inhibitors:阻害薬のグローバル市場2014(薬開発、治験動向)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DelveInsight’s,“Protein Kinase C (PKC) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Protein Kinase C (PKC) Inhibitors. This report provides information on the therapeutic development based on the Protein Kinase C (PKC) Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of Protein Kinase C (PKC) Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Protein Kinase C (PKC) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Protein Kinase C (PKC) Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

• Complete MOA intelligence and complete understanding over therapeutics development for Protein Kinase C (PKC) Inhibitors
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Protein Kinase C (PKC) Inhibitors pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

*** レポート目次(コンテンツ)***

• Protein Kinase C (PKC) Inhibitors Overview
• Protein Kinase C (PKC) Inhibitors Disease Associated
• Protein Kinase C (PKC) Inhibitors Pipeline Therapeutics
• Protein Kinase C (PKC) Inhibitors Therapeutics under Development by Companies
• Protein Kinase C (PKC) Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Protein Kinase C (PKC) Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Protein Kinase C (PKC) Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Protein Kinase C (PKC) Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Protein Kinase C (PKC) Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Protein Kinase C (PKC) Inhibitors – Discontinued Products
• Protein Kinase C (PKC) Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Protein Kinase C (PKC) Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for Protein Kinase C (PKC) Inhibitors by Therapy Area, 2014
• Number of Products under Development for Protein Kinase C (PKC) Inhibitors, 2014
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
• Drug Candidates Profiles
• Protein Kinase C (PKC) Inhibitors Assessment by Monotherapy Products
• Protein Kinase C (PKC) Inhibitors Assessment by Combination Products
• Protein Kinase C (PKC) Inhibitors Assessment by Route of Administration
• Protein Kinase C (PKC) Inhibitors Assessment by Stage and Route of Administration
• Protein Kinase C (PKC) Inhibitors Assessment by Molecule Type
• Protein Kinase C (PKC) Inhibitors Assessment by Stage and Molecule Type
• Protein Kinase C (PKC) Inhibitors Therapeutics – Discontinued Products
• Protein Kinase C (PKC) Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2014

• Number of Products under Development for Protein Kinase C (PKC) Inhibitors by Therapy Area, 2014
• Number of Products under Development for Protein Kinase C (PKC) Inhibitors, 2014
• Late Clinical Stage Products (Filed and Phase III), 2014
• Mid Clinical Stage Products (Phase II), 2014
• Early Clinical Stage Products (Phase I and IND Filed), 2014
• Discovery and Pre-Clinical Stage Products, 2014
• Protein Kinase C (PKC) Inhibitors Assessment by Monotherapy Products
• Protein Kinase C (PKC) Inhibitors Assessment by Combination Products
• Protein Kinase C (PKC) Inhibitors Assessment by Route of Administration
• Protein Kinase C (PKC) Inhibitors Assessment by Stage and Route of Administration
• Protein Kinase C (PKC) Inhibitors Assessment by Molecule Type
• Protein Kinase C (PKC) Inhibitors Assessment by Stage and Molecule Type

*** レポートのキーワード ***

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • SJI Inc. (2315):企業財務及びSWOT分析(IT・通信業界)
    Summary This comprehensive SWOT profile of SJI Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportu …
  • 世界の電子用弗化水素酸市場2016
    Notes:Production, means the output of Electronic Grade Hydrofluoric Acid Revenue, means the sales value of Electronic Grade Hydrofluoric Acid This report studies Electronic Grade Hydrofluoric Acid in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses …
  • Ausgrid(代替エネルギー分野):企業M&A動向
    Summary Ausgrid, formerly, EnergyAustralia, is a state-owned corporation. The company supplies electricity to customers in Sydney, Central Coast and Hunter Region in New South Wales. Its major activities include asset ownership and management of electricity distribution and transmission network; off …
  • ESP(電動水中ポンプ)の世界市場:Borewell水中ポンプ、Openwell水中ポンプ
    About ESP A submersible pump is a type of artificial lift system (ALS), which is completely submerged in the fluid to be pumped. It is also referred to as ESP. The basic operation of ESPs is based on the principle that they push, rather than pull, the fluid being dealt with. They are usually feature …
  • Hexza Corporation Berhad (HEXZA):企業概要及び財務・戦略的SWOT分析
    Hexza Corporation Berhad (HEXZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • 磁気共鳴画像診断(MRI)装置の世界市場
    MediPoint: Magnetic Resonance Imaging Systems - Global Analysis and Market Forecasts Summary The global magnetic resonance imaging (MRI) market is a shifting, capital equipment market that is saturated with numerous players developing innovative technologies. Given their impressive safety and effica …
  • EDP Renewables North America LLC(代替エネルギー分野):企業M&A動向
    Summary EDP Renewables North America LLC (EDPR NA), formerly Horizon Wind Energy, is a developer of wind energy. It operates as the developer, constructor, owner and operator of wind farms in North America. The company owns and operates 28 wind farms with offices across the US and Canada. It has dev …
  • NTT DATA Corporation (9613) : 企業概要及びSWOT分析
    This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. WMI's 'NTT DATA Corporation (9613) : Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, whi …
  • N-メチル-N,N-ジエタノールアミンの世界市場2019
    The Global N-Methyl-N,N-Diethanolamine (CAS 105-59-9) Industry 2019 Market Research Report is a professional and in-depth study on the current state of the N-Methyl-N,N-Diethanolamine industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, appl …
  • ホットメルト系包装用接着剤の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2022)
    The hot melt adhesives are defined as adhesives that melt and flow on application of heat and solidify on cooling to give a strong adhesion. They are applied in a molten state at temperatures that range from 120°C to 180°C depending on applications and materials to be bonded. Scope of the Report: Th …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIMR2014588 )"Protein Kinase C (PKC) Inhibitors:阻害薬のグローバル市場2014(薬開発、治験動向)" (英文:Protein Kinase C (PKC) Inhibitors -Pipeline Insights, 2014)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。